H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral
Tweet
Share
E-mailGet Alerts RAPT Hot Sheet
Price: $58.02 --0%
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 18 | New: 50
Rating Summary:
7 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 18 | New: 50
Join SI Premium – FREE
H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral with a price target of $58.00.
For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.
Shares of Rapt Therapeutics closed at $35.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Insmed (INSM) at Outperform
- Krystal Biotech to join S&P MidCap 400, Tutor Perini and V2X to join S&P SmallCap 600
- Luxxfolio closes $1.55M private placement to fund crypto projects
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
